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Available online 21 June 2016Background: Lipoprotein lipase (LPL) is a multifunctional protein and a key enzyme involved in the regulation of
lipoprotein metabolism. We determined the lipoproteins to which LPL is bound in the pre-heparin and post-
heparin plasma.
Methods: Tetrahydrolipstatin (THL), a potent inhibitor of serine lipases, was used to block the lipolytic activity of
LPL, thereby preventing changes in the plasma lipoproteins due to ex vivo lipolysis. Gel ﬁltration was performed
to obtain the LPL elution proﬁles in plasma and the isolated remnant lipoproteins (RLP).
Results:When ex vivo lipolytic activity was inhibited by THL in the post-heparin plasma, majority of the LPL was
found in the VLDL elution range, speciﬁcally in the RLP as inactive dimers. However, in the absence of THL, most
of the LPL was found in the HDL elution range as active dimers. Furthermore, majority of the LPL in the pre-
heparin plasma was found in the RLP as inactive form, with broadly diffused lipoprotein proﬁles in the presence
and absence of THL.
Conclusions: It is suggested that during lipolysis in vivo, the endothelial bound LPL dimers generates RLP, forming
circulating RLP-LPL complexes in an inactive form that subsequently binds and initiates receptor-mediated
catabolism.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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(RLP-C)1. Introduction
Lipoprotein lipase (LPL) hydrolyzes the triglyceride-rich core of chy-
lomicrons (CM) and very low density lipoproteins (VLDL). It is also
known as a ligand, in vitro or in vivo, for the binding of lipoproteins to
the low density lipoprotein receptor-related protein 1 (LRP-1) and
may play a central role in the receptor-mediated removal of triglyceridesity lipoproteins; HTGL, hepatic
-related protein 1; LPL, lipopro-
P-C, remnant-like lipoprotein
particles-triglyceride; TC, total
L, very low density lipoprotein.
Laboratory Medicine, Gunma
achi, Maebashi, Gunma, Japan.
.rich lipoproteins [1–3]. After synthesis in parenchymal cells, primarily
in adipose tissue and skeletal muscle, LPL is transported to the intimal
surface of the vascular endothelium, where it is non-covalently an-
chored to the heparan sulfate side chains of membrane proteoglycans
and the recently discovered GPI-HBP1 [1,4,5]. At this site, LPL is respon-
sible for the hydrolysis of the TG-rich core of circulating CM and VLDL,
generating free fatty acids that can be either used immediately for ener-
gy or stored, primarily in adipose tissue under normal circumstances.
The enzyme is known to be active only in a dimeric conﬁguration [6,
7]. To carry out its functions, LPL binds the interface of TG-rich lipopro-
teins [8,9]. After reduction in TG content and size, CM and VLDL rem-
nants are believed to detach from the endothelium and released into
the circulation by mechanism(s) that have yet to be fully understood
[10,11].
The aim of this studywas to clarify the characteristics of the interac-
tion between LPL and remnant lipoproteins (RLP) in both pre-heparin
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the ex vivo lipolytic activity of LPL in the post-heparin plasma in this
study. The relationship between LPL activity and its inhibitors (apoC1
and apoC3) in RLP was also investigated.
There is growing evidence that LPL not only affects lipolysis, but also
acts as a ligand for the binding of lipoprotein particles to receptors on
the cell surface. A number of studies have reported that LPL is associated
with lipoproteins in humanpre- and post-heparin plasma, in both its in-
active and active form [12–14]. Felts, ltakura, and Crane [15] in 1975
suggested that LPL binds to lipoprotein remnants and may be a marker
for uptake of remnant lipoproteins by the liver. However, the isolation
of LPL bound remnants from TG-rich lipoproteins or VLDL, namely the
LPL-remnant complex, in plasma has not been demonstrated at this
time.
Previous studies showed that LPL bound to apolipoprotein E-rich li-
poproteins enhances their binding to the LRP-1 in vitro, the putative re-
ceptor for CM remnants [16], as well as to the VLDL receptor [17,18].
Moreover, Nykjaer et al. [19] suggested that only the LPL dimer, and
not the monomer, was able to mediate this binding. Goldberg et al.
[12] reported that lipolytic activity in the pre- and post-heparin plasma
is associated with cholesterol-rich particles slightly larger than LDL.
Other reports conﬁrmed this observation by showing that the LPL pro-
tein after gel ﬁltration is associated with LDL and HDL in both pre-
heparin and post-heparin plasma [13,14]. In these studies, however,
no steps were taken to inhibit lipolytic activity ex vivo. Zambon, Hashi-
moto, and Brunzell [20] demonstrated that a signiﬁcant amount of the
TG-rich core of CM and VLDL can be hydrolyzed in the post-heparin
plasma stored ex vivo even at 4 °C if the LPL activity is not effectively
inhibited. It is, therefore, possible that when heparin is administered,
LPL is initially released associated with VLDL particles that undergo fur-
ther hydrolysis by LPL ex vivo, resulting in lipoproteins with an LDL and
HDL size range. However, more recently Zambon et al. [21] reported
that dimeric LPL is bound to triglyceride-rich plasma lipoproteins in
the presence of THL [22,23] as the result of an inhibition of ex vivo
lipolysis.
The present study, we analyzed LPL binding to RLP isolated from
post-heparin and pre-heparin plasmaby immunoafﬁnity gel separation.
By inhibiting lipolytic activity ex vivo, this study aimed to examine: 1) li-
poprotein subclass with which LPL is associated in vivo before and after
heparin administration as well as in the presence and absence of THL,
2) whether the LPL bound to RLP isolated by immunoafﬁnity gel are di-
mers or monomers and with an active or inactive form, and 3) whether
the association between LPL and lipoproteins previously observed in the
post-heparin plasma reﬂects a physiological or non-physiological condi-
tion. To clarify these biochemical and physiological characteristics of the
LPL and RLP interactionwill provide the critical new insight into the def-
inition of remnant lipoproteins.
2. Materials and methods
2.1. Subjects
Randomly selected type 2 diabetes mellitus (T2DM) and metabolic
syndrome (MetS) patients (aged 23–77 y; males 101, females 94)
who were under treatment at Gunma University Hospital, Maebashi,
Japan were studied in cases with plasma TG levels above and below
150 mg/dl. The study had the approval of the Ethical Committee of the
Gunma University School of Medicine. Written informed consent was
obtained from all of the participants.
The post-heparin plasma study was conducted as part of a trial in-
vestigating the metabolic effects of sugar consumption at University of
California, Davis [24,25]. The participants,whowere young and general-
ly healthy, received intravenous administration of heparin for measure-
ments of LPL and hepatic triglyceride lipase (HTGL) activity. The 29
samples analyzed for the current study were from 15 male and 14 fe-
maleswhowere overweight or obese and susceptible to bepostprandialremnant hyperlipoproteinemia (median age 24 y, with an average BMI
of 27 kg/m2). The post-heparin plasmawas collected in the fasting state
at 8:00 a.m. in themorning. TheUCDavis Institutional ReviewBoard ap-
proved the experimental protocol and all of the subjects provided writ-
ten informed consent to participate in the study. All of the plasma
samples were kept frozen at−80 °C until analysis.
2.2. Plasma handling
The pre- and post-heparin plasma samples were obtained after 12-h
fasting. The post-heparin plasma was collected at 15 min after i.v. ad-
ministration of 50 U/kg body weight of heparin at UC Davis. In addition,
a normotriglyceridemic (male aged 60 y) and a hypertriglyceridemic
Japanese subject (male aged 32 y) were injected with 30 U/kg of hepa-
rin and the plasmawas collected at 0, 15, 30, 60 min at Hidaka Hospital,
Takasaki, Japan.
To inhibit lipolytic activity ex vivo, 1 aliquot of post-heparin blood
wasmixed with tetrahydrolipstatin (THL) (Orlistat, Sigma-Aldrich) im-
mediately after blood withdrawal at a ﬁnal concentration of 1 μg/ml
[21]. Plasmawas separated from the THL-added blood by centrifugation
(1800g, 10 min at room temperature).
2.3. Assay procedure for sandwich LPL-ELISA
The LPL concentration in plasma was measured using the LPL-ELISA
newly developed at Immuno-Biological Laboratories (IBL). The assay
used 2 different monoclonal antibodies against human recombinant
LPL (57A5 and 88B8) for the sandwich ELISA. Tetra methyl benzidine
(TMB) was used as the coloring agent (chromogen). Brieﬂy, 100 μl of
plasma or standard LPL diluted N100 fold was incubated with a solid
phase antibody (57A5) for 60 min at 37 °C using a plate lid. After wash-
ing the plate with phosphate buffer, another antibody (88B8) labelled
with horse radish peroxidase was added and incubated for 30 min at
4 °C with the plate lid. After washing, chromogen was added and incu-
bated for 30 min at room temperature. The plate was read at 450 nm
against a reagent blankwithin 30min of the addition of 1 NH2SO4 solu-
tion to stop the reaction. Themeasurement range of the assaywas 0.02–
1.5 ng/ml. The CV was b10% in both intra- and inter-assay
2.4. LPL activity assay
The LPL activities were determined by an assay developed by
Imamura et al. [26] for measuring the increase in absorbance at
546 nm due to the quinoneine dye. Reactionmixture-1 (R-1) contained
dioleoylglycerol solubilized with lauryldimethylaminobetaine,
monoacylglycerol-speciﬁc lipase, glycerolkinase, glycerol-3-phosphate
oxidase, peroxidase, ascorbic acid oxidase and apolipoprotein C-II
(apoC-II). R-2 contained Tris-HCl (pH 8.7) and 4-aminoantipyrine.
Assay of lipase activity was performed with a chemistry analyzer
(H7700P). In the assay for LPL activity, 160 μl of R-1 was incubated at
37 °C with 2 μl of sample for 5 min, and 80 μl of R-2 was added and in-
cubated for additional 5 min. HL activities were measured under the
same conditions without apoC-II.
2.5. Isolation of remnant lipoproteins with the immunoafﬁnity gel
Immuno-separation method [27] was used to isolate RLP containing
both apoB-48 and apoB-100 from the plasma using speciﬁc antibodies
so as to isolate the RLP as an unbound fraction. Brieﬂy, 0.5 ml aliquots
of plasmawere applied to 5 ml of immunoafﬁnity mixed gel containing
2monoclonal antibody clones,Mab JI-H raised against human apoB-100
and Mab H-12 raised against human apoA-I (JIMRO) with gentle shak-
ing for 2 h at room temperature. The unbound fraction was concentrat-
ed to the same volumeof plasmaused for the preparation of RLPwith an
Amicon Ultra ﬁlter (Millipore) for the gel ﬁltration analysis.
Table 1
LPL concentration in plasma and RLP in cases with normal and high TG concentration.
TG b 150 mg/dl (n =
154)
TG ≧ 150 mg/dl (n =
41)
p
Value
TC (mg/dl) 200 ± 39 217 ± 41 b0.01
TG (mg/dl) 107 ± 30 253 ± 100 b0.01
LDL-C (mg/dl) 83 ± 27 98 ± 25 b0.01
HDL-C (mg/dl) 57 ± 13 46 ± 11 b0.01
sdldl (mg/dl) 23 ± 10 42 ± 14 b0.01
RLP-C (mg/dl) 4.9 ± 1.7 12.2 ± 4.9 b0.01
RLP-TG (mg/dl) 15.6 ± 10.5 63.2 ± 60.2 b0.01
Plasma LPL (ng/ml) 98 ± 27 80 ± 28 b0.05
RLP-LPL (ng/ml) 86 ± 25 67 ± 23 b0.05
RLP-LPL/Plasma-LPL (%) 87 ± 7 85 ± 13 N.S.
RLP-LPL/RLP-TG (%) 5.5 1.1 b0.01
ApoC-III (mg/dl) 7.6 ± 2.1 12.0 ± 3.3 b0.01
Table 2
LPL concentration in plasma and RLP fraction in pre- and post-heparin plasma of 29
healthy volunteers.
Pre-heparin Post-heparin p Value
TC (mg/dl) 174 ± 33 169 ± 32 N.S.
TG (mg/dl) 139 ± 78 103 ± 58 b0.01
LDL-C (mg/dl) 102 ± 28 100 ± 27 N.S.
HDL-C (mg/dl) 49 ± 13 47 ± 12 N.S.
RLP-C (mg/dl) 7.2 ± 4.6 6.7 ± 4.1 N.S.
RLP-TG (mg/dl) 45 ± 37 26 ± 24 b0.01
RLP-TG/RLP-C (%) 6.0 ± 1.7 3.5 ± 1.4 b0.01
Plasma-LPL (ng/ml) 81 ± 27 438 ± 95 b0.01
RLP-LPL (ng/ml) 62 ± 26 117 ± 30 b0.01
RLP-LPL/Plasma-LPL (%) 77 ± 11 27 ± 5 b0.01
RLP-LPL/RLP-TG (%) 1.4 ± 0.7 4.5 ± 0.8 b0.01
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The isolated RLP sample or plasma was subjected to 12% SDS-
polyacrylamide gel electrophoresis and the proteins in the gel were
transferred to a polyvinylidene diﬂuoridemembrane (ProBlott; Applied
Biosystems) by electroblot. The membranes were blocked with 5% dry
milk for 2 h and incubated with primary antibodies for 16 h. The mem-
braneswere then incubatedwith a second antibody conjugatedwith al-
kaline phosphatase for 2 h, then visualized using the nitro blue
tetrazolium/5-bromo-4-chloro-3-indolylphosphate p-toluidine salt sys-
tem. Anti-apolipoprotein A-I antibody (600-101-109) was from
Rockland and anti-apolipoprotein B-100 antibody (20H-G1b) was
from the Academy Bio-Medical Co.
2.7. Gel ﬁltration chromatography
Gel ﬁltration chromatography of the pre- and post-heparin plasma
and RLP was performed at room temperature by fast protein liquid
chromatography (FPLC) (Pharmacia LKB) to separate the lipoproteins
in phosphate-buffered saline (PBS). The system was programmed (Liq-
uid Chromatography Controller LCC-500 Plus) to load and separate
samples on a 50-cm column (16 mm internal diameter) packed with
cross-linked agarose gel (Superose 6B grade, Pharmacia). The column
was eluted with PBS at a rate of 1.0 ml/min, and 25 min after addition
of sample, 50 × 1 ml fractions were collected sequentially. Sample elu-
tion was monitored spectrophotometrically at optical density 280 nm.
VLDL-, LDL-, and HDL-sized fractionswere pooled according to the opti-
cal density elution proﬁle.
2.8. Lipid and lipoprotein measurements
After a 12-h overnight fast, blood samples were taken, then plasma
was isolated and stored at 4 °C. The following analytes were measured
within 48 h of drawing the blood: total cholesterol (TC), triglycerides
(TG), direct low density lipoprotein cholesterol (LDL-C), HDL-C and
small dense LDL- cholesterol (sdlDL-C) (Denka-Seiken). Aliquots of
serumwere stored at−80 °C for subsequent determination of parame-
ters. RLP-C and RLP-TG assay (JIMRO II) was obtained from Otsuka
(Tokyo, Japan) [28]. ApoB100 ELISA from IBL and apoA1, apoC1 and
apoC3 ELISAwere purchased fromAbnova. Lipid parameters weremea-
sured with a Hitachi 917 Analyzer.
2.9. Statistical analysis
Statistical analyses were conducted with SPSS II (ver. 11.0.1 J) and
StatFlex ver. 6 (Artech). All values are expressed asmeanswith standard
deviations. Differences between groups were tested using the unpaired
Student's t-test for normally distributed data and the Mann-Whitney U
Test for skewed data. Pearson or Spearman analysis was used for para-
metric or non-parametric variables to determine the correlations be-
tween parameters. A P b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Subjects
Table 1 shows the lipid and lipoprotein concentrations, RLP-TG/RLP-
C ratio, apo CIII and LPL concentration in pre- heparin plasma. The data
are presented asmean valueswith standard deviations. The results indi-
cated that over 80% of the LPL in circulating pre-heparin plasma was
found in the RLP fraction. The LPL concentrationwas signiﬁcantly higher
in plasma with TG b 150 mg/dl than TG ≧ 150 mg/dl (p b 0.05). This
shows that the ratio of LPL bound to RLP (RLP-LPL/RLP-TG ratio) was
signiﬁcantly higher in the normal TG cases than in the high TG cases
(p b 0.01). A larger number of LPL was bound to RLP in the normal TG
plasma and hydrolyzed RLP more effectively than in high TG plasma.Table 2 presented the lipid and lipoprotein levels in the fasting, pre-
heparin and post-heparin plasma (15min after heparin administration)
in the 29 subjects. Lipids, lipoproteins and the LPL concentration in plas-
ma and in RLP were determined. Approximately 80% of the LPL concen-
trationwas found in RLP derived from circulating plasma (pre-heparin),
while b30% of the LPL concentration was found in RLP in the post-
heparin plasma. This means that N70% of the LPL concentration was de-
tected in non-RLP fraction in the post-heparin plasma. The LPL concen-
tration in post-heparin RLP increased approximately ≥2 fold compared
to LPL in pre-heparin RLP. Signiﬁcantly increased LPL bound to RLP
(RLP-LPL) was found in the post-heparin plasma associated with a sig-
niﬁcant decrease in RLP-TG (p b 0.01). This means that LPL detached
from the endothelium bound to RLP directly in circulating blood and
generated smaller RLP particles (a reduced RLP-TG/RLP-C ratio).
3.2. Establishment of 2 kinds of highly sensitive and speciﬁc LPL sandwich
ELISA methods
Two kinds of antibodies were used for the ELISA, the 57A5 and 88B8
antibodies against human recombinant LPL. Both of the 57A5 and 88B8
antibodies recognize the C-terminal region of the LPL protein. Neither
monoclonal antibody by itself detects the monomeric recombinant LPL
by the sandwich ELISA method, recognizing only the dimeric (or poly-
meric) LPL that is known to be the active form. Fig. 1 shows the signiﬁ-
cantly high correlation between the LPL activity & LPL concentration
(mass) by 2 MoAb (57A5-88B8) ELISA (Fig. 1 (A) (p b 0.001) and 1
MoAb (88B8-88B8) ELISA (Fig. 1 (B) (p b 0.001). Also as shown in
Fig. 1 (C), a signiﬁcantly high correlation was found between the 1
MoAb and 2MoAb assay in thepost-heparin plasma (p b 0.001), indicat-
ing that the singleMoAb-ELISA detected the dimeric or polymeric LPL in
the active form. The 2 antibody ELISA detected all of the LPL, i.e. both the
monomeric and dimeric LPL. As the recombinant LPL with amonomeric
form did not react with this 1 MoAb (88B8-88B8) ELISA, this method
allowed a speciﬁc assay for dimeric LPL detection in the plasma. Fig. 1
(D) shows the signiﬁcantly high correlation between the 1 MoAb and
Fig. 1. Correlation between LPL activity and the LPL concentration (mass) along with a comparison of LPL-ELISA between the 1 MoAb and 2 MoAb systems. A. LPL activity vs 2 MoAb
sandwich assay (57A5 and 88B8) in the post-heparin plasma. B. LPL activity vs 1 MoAb sandwich assay (88B8-88B8) in the post-heparin plasma. Comparison between 2 MoAb
sandwich assay (57A5 and 88B8) and 1 MoAb sandwich assay (88B8-88B8) in the post-heparin plasma (C) and in the pre-heparin plasma (D). Two MbAb and 1 MoAb LPL sandwich
assay were highly correlated (p b 0.001) in both pre-heparin and post-heparin plasma.
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strongly suggest thatmost of the LPL in the pre-heparin plasmawas in a
dimeric form, although the LPL activity in pre-heparin plasma was un-
detectable (i.e. very low activity) as known by previous literatures.
However, the absolute concentration of LPL determined by the 2
methods was not exactly the same, approximately 60% of LPL concen-
tration was determined by the 1 MoAb-ELISA compared with the 2
MoAb-ELISA using the same LPL calibrator. The different reactivity of
the antibodies to the LPL calibrator may have caused this difference,
but the result showed signiﬁcantly high correlation between the 2
LPL-ELISA methods. Therefore, we have concluded that most of the
LPL in the post-heparin and pre-heparin plasma was in the dimeric
form, as previously reported by Brunzell et al. [21].
3.3. Characteristics of the LPL dimers in plasma and in RLP after heparin ad-
ministration in the presence and absence of THL
LPL dimers in the post-heparin plasma and in RLP fraction of a nor-
mal (Case 1) and a hypertriglyceridemic (Case 2) subject as representa-
tive cases were demonstrated in a time dependent manner after
heparin administration. LPL dimers in pre-heparin plasma were N2-
fold higher in Case 1 (low RLP-C) compared to Case 2 (high RLP-C).
Post-heparin plasma was collected from the 2 cases at 0, 15, 30,
60 min and the LPL dimers (Fig. 2) were determined along with the
lipid and lipoprotein proﬁles (Table 3). The plasma LPL dimers and ac-
tivity (data not shown) increased most signiﬁcantly at 15 min and
then decreased in parallel to the basal levels (RLP-LPL levels). The
in vitro addition of THL immediately after blood withdrawal did not af-
fect the LPL dimer concentration, but it did completely inhibit the LPL
activity. The TG and RLP-C levels signiﬁcantly decreased, followed by
an increase in the LPL dimers after heparin administration in Case 2,
but did not show signiﬁcant change in Case 1 because of the lowconcentrations of TG and RLP-C (Table 3). The LPL dimers in the RLP
were also increased at 15 min (Fig. 2) as in the case of the plasma LPL,
but they did not decrease as rapidly as LPL in plasma. Therefore, the
half-life of LPL in RLP was much longer than that of the LPL bound to
non-RLP fraction in plasma.
The LPL dimer immunoreactivity (concentration) determined in the
post-heparin plasma (active form)was signiﬁcantly decreased at 15 and
30 min after 2 h pre-incubation at 37 °C in the absence of THL (Fig. 3
(A)), which decreased almost to the LPL dimer levels in RLP. However,
in the presence of THL, the immunoreactivity of the LPL dimers (inactive
form) did not change after 2 h pre-incubation at 37 °C (Fig. 3 (B)). These
results suggest LPL dimers in post-heparin plasma having activity
ex vivo is easily degraded to the level in RLP in plasma, while the LPL di-
mers in RLP was resistant to degradation (Fig. 3 (C)). LPL dimers in the
RLP remained unchanged at 37 °C pre-incubation for 2 h in the presence
and absence of THL. Therefore, those results suggest that LPL dimers in
RLP were inactive because of no effect of THL on degradation of LPL di-
mers. These results clariﬁed that there were 2 kinds of LPL dimers in
post-heparin plasma, active form in non-RLP fraction and inactive
form in RLP.
Furthermore, LPL dimers in RLP in pre-heparin plasma were consis-
tently increased approximately 10 to 30% after 37 °C incubation for 2 h.
These results suggest the possibility that there were approximately 20%
of LPL dimers bound to non-RLP in pre-heparin plasma, and shifted to
RLP after 2 h incubation at 37 °C.
3.4. The LPL distribution and lipoprotein elution proﬁles obtained by gel ﬁl-
tration chromatography
An immuno-separation method was used to isolate RLP from the
post-heparin and pre-heparin plasma in the presence or absence of
THL to investigate which lipoprotein subclass LPL dimers bound. RLP
Fig. 2. LPL concentration in the post-heparin plasma and RLP at 0, 15, 30, 60 min after
heparin administration in normal (case 1) and hypertriglyceridemic (case 2) cases.
Plasma LPL and LPL in the RLP signiﬁcantly high in case 1 than in case 2 and increased at
15 min after heparin administration, but decreased nearly to the basal level in 60 min.
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shown by SDS-PAGE electrophoresis and Western blot analysis in the
presence or absence of heparin administration (Fig. 4 A)
To demonstrate the effect of ex vivo lipolysis in the presence and ab-
sence of THL on the LPL distribution across the entire lipoprotein elution
range, the post-heparin plasma was analyzed by Superose 6B gel ﬁltra-
tion. An aliquot of post-heparin plasmawas collected in the presence of
THL and applied to the FPLC column. As shown in Fig. 5 (A), a large
amount of the LPL dimers was found in the VLDL elution range, with
minor peaks in the LDL and HDL elution range. However, in another al-
iquot of post-heparin plasma in the absence of THL (Fig. 5 (A)), a small
amount of the LPL dimers was found in the VLDL elution range, with
major peaks shifted to the HDL elution range. No signiﬁcant amount of
free LPL protein was found in plasma both in the presence and absence
of THL.
The RLP fractions isolated from the post-heparin plasma by immu-
noafﬁnity gel in the presence or absence of THL were also applied to
the FPLC column (Fig. 5 (B)). In the presence of THL, a large amount of
the LPL dimer was found in the VLDL elution range with minor LDL
and HDL elution range peaks, a pattern which was very similar withTable 3
Plasma TG and RLP-C concentration in post-heparin plasma at 0, 15, 30, 60min after hep-
arin injection.
Plasma-TG (mg/dl) RLP-C (mg/dl)
Time (min) 0 15 30 60 0 15 30 60
Case 1 64 48 44 50 3.3 3.0 3.2 3.4
Case 2 213 100 120 160 25.3 11.1 14.2 20.4the elution proﬁle in the post-heparin plasma. However, in the absence
of THL (Fig. 5 (B)), no LPL dimers were found in the VLDL elution range,
with a certain amount in the HDL elution range. These results suggest
that THL inhibited LPL activity ex vivo and signiﬁcantly affected the elu-
tion proﬁles of the LPL dimers in RLP as in plasma. The reason why the
LPL dimers in RLP were signiﬁcantly decreased in the absence of THL
was probably due to the conformational changes of RLP during the iso-
lation procedure from plasma at room temperature; the dissociation of
apoE or other apolipoproteins from RLP, which blocks the epitope of
anti-apoB100 (JI-H) antibody [27]. Therefore, LPL dimers in RLP de-
creased signiﬁcantly with the decrease of RLP (apoB100) shown as gel
ﬁltration proﬁle (Fig. 4 C).
The pre-heparin plasma and RLP isolated from the pre-heparin plas-
ma in the presence and absence of THLwere applied to the FPLC column
(Fig. 5 (C) and (D)). A small amount of the LPL dimers both in the plas-
ma and RLP in the presence and absence of THLwere found very similar
in the VLDL, LDL and HDL elution rangewith a broad proﬁle of diffusion.
These elution proﬁles were similar to the ones of the RLP isolated from
the post-heparin plasma in the absence of THL. No effect of the presence
of THL on ex vivo lipolysiswas foundboth in the pre-heparin plasma and
RLP. Because the LPL dimers in the pre-heparin plasma had negligible
LPL activity ex vivo, the isolation procedure of the RLP by the immunoaf-
ﬁnity gel did not affect the elution proﬁles of the LPL dimers. Free LPL di-
mers, unbound to the lipoproteins, were not found in the elution range
of low molecular weight by this gel ﬁltration method in pre-heparin
plasma.
3.5. Inhibition of LPL activity by apoC1 and C3 in the post-heparin plasma
RLP has been reported to be apoC3 and apoE-rich in cases of in-
creased RLP-C, but low apoC3 level in RLP in cases of normal RLP-C
[29]. Fig. 6 shows that apoC1 (A), apo C3 (B) and apoE (C) in RLP were
found in the VLDL and apoE-rich HDL elution ranges by gel ﬁltration
chromatography. Although apoE-rich HDL is contained in RLP, LPL di-
mers were not found in this fraction in the presence of THL as show in
Fig. 5 (B). Also the presence of THL did not affect the elution proﬁles
of these apolipoproteins.
LPL activity was not detected in RLP isolated from the post-heparin
plasma aswell as in pre-heparin plasma (Table 3). Table 3 also indicates
that the addition of apoC1 and apoC3 in the LPL activity assay system
[26] with the same concentration (5 μg) of apoC2 (activator) inhibited
LPL activity, speciﬁcally strong inhibition was observed by apoC1.
These results suggest the possibility that the LPL dimers in RLP are inac-
tive because of the presence of co-localized inhibitors such as apoC1 and
C3 in the remnant lipoprotein particles (Fig. 7).
4. Discussion
We report LPL binding directly to plasma remnant lipoprotein parti-
cles (RLP-LPL complex) which we have reported as RLP since 1993
[27–31]. In particular, we used THL for the inhibition of the ex vivo lipo-
lytic activity of LPL to minimize the risk of artifacts after blood with-
drawal. The results show the following. 1) More than 80% of
circulating LPL in pre-heparin plasmawas found in RLP as RLP-LPL com-
plex. 2) The circulating LPL found in RLP in the pre- and post-heparin
plasmawas shown as LPL dimers but in the inactive form. 3)When lipo-
lytic activity was inhibited by THL in the post-heparin plasma, most LPL
dimers were found in the VLDL elution range, speciﬁcally in the RLP.
When the ex vivo lipolytic activity was not inhibited by THL, the LPL di-
mers became transitional in thepost-heparin plasmaand shifted rapidly
to the HDL elution range. 4) Two different type of LPL dimers were
found in post-heparin plasma; one is active form found mostly in HDL
elution range, the other is inactive form found in RLP. 5) The proposed
model of the RLP-LPL complex shows that when LPL is detached from
the endothelium surface, LPL is mostly released as the complex with
RLP and inhibitors (apoC1, C3) into the blood. The results reported
Fig. 3. The LPL concentration in the post-heparin plasma and RLPwith andwithout pre-incubation at 37 °C for 2 h. As shown in (A), LPL in total plasma, after 2 h 37 °C incubation, LPL levels
signiﬁcantly decreased at 15 and 30min. However, in the present of THL, the decrease of plasma LPLwas inhibited (B). LPL in RLP did not change in the presence or absence of THL after 2 h
37 °C incubation (C). Plasma LPL levels after 2 h 37 °C incubation decreased almost to the same level with LPL in RLP.
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gest the need of a new deﬁnition of remnant lipoproteins in the plasma.
There has been no report that LPL is a speciﬁc component of remnant li-
poproteins isolated from both pre- and post-heparin plasma.
Post-heparin plasma has been convenient means of measuring LPL
activity for a diagnostic purpose, because it has been difﬁcult tomeasure
the LPL protein or identify its different plasma forms until recently.
Therefore, previous studies have been focused on the measurement of
LPL catalytic activity after heparin administration. However, the LPL ac-
tivity in the post-heparin plasma has been known to be generally unsta-
ble and non-physiological compared to the LPL protein concentration in
pre-heparin plasma. Recently, Shirakawa et al. [32,33] reported a com-
parative study of the LPL activity and mass (concentration) in the pre-
and post-heparin plasma, suggesting that the determination of the LPL
concentration in thepre-heparin plasmamay take theplace of LPL activ-
ity andmass in the post-heparin plasma for clinical diagnostic purposes.
This is also supported by other previous reports as well [34,35].
In this study, we ﬁrst investigated the protein structure of LPL, i.e.,
whether LPL is dimer or monomer, in the pre-and post-heparin plasma,
using a newly developed sandwich ELISA made up of a 1 MoAb and 2
MoAb system. In the post-heparin plasma, the majority of the LPL pro-
tein is known to be in the active, dimeric form, but most of the LPL pro-
tein in the pre-heparin plasma has been known to be inactive form [36,
37]. A single MoAb sandwich ELISA was unable to detect monomeric
LPL, detecting only dimeric (or polymeric if any) LPL, which is known
to be the active form. A signiﬁcantly high correlation was found be-
tween the 1 MoAb and 2 MoAb ELISA and activity assays in the post-
heparin plasma. Moreover, as shown in Fig. 1 (D), even in the pre-
heparin plasma, the 1 MoAb ELISA was signiﬁcantly correlated with
the 2 MoAb ELISA. These ﬁndings suggest that most of the LPL in thepre-heparin plasma as well as the post-heparin plasma are in a dimeric
form. These ﬁndings are important because no reports have previously
described the predominant presence ofmonomer, polymer or degraded
LPL in plasma under physiological conditions. These results are also in
agreementwith those of Brunzell et al. [21,36], who reported previously
that most LPL in plasmawas in the dimeric form by using an ELISA with
5D2 and 5F9monoclonal antibodies. Although the antibodies (57A5 and
88B8) we used in this study were different from Brunzell's antibodies,
the recognition site of antibodies were similar at C-terminal. Therefore,
we have used the term “LPL dimers” to represent the “LPL concentra-
tion” in this manuscript. Furthermore, we used mostly the 2 MoAb
sandwich ELISA in this study, because the assay was highly sensitive
and was able to determine an LPL concentration of N20 pg/ml, which
made it possible to determine the LPL dimers in the fractionated gel ﬁl-
tration chromatography aliquots.
RLP isolation was performed by an immunoafﬁnity gel separation
method [27]. The lipoproteins isolated by this method exhibit the typi-
cal characteristics of remnant lipoproteins [31], but there has been a
need to explain more speciﬁc characteristics of remnant lipoproteins.
As predicted by Felts et al. [15], the direct binding of LPL with RLP in
plasma would provide the most convincing proof that RLP is identical
with the circulating remnant lipoproteins in the plasma. RLP as “Rem-
nant like-Lipoprotein Particles” were ﬁrst named by Havel (1993), a
term meant to designate TG-rich lipoproteins with apoE-rich, apoC3-
rich and cholesteryl-ester rich VLDL [27–31]. The presence of LPL has
never been included as a component of remnant lipoproteins. There-
fore, this study has added a new characteristic of remnant lipoproteins
that majority of the LPL in the circulating plasma is RLP-bound, particu-
larly in the pre-heparin plasma. As LPL is known to bind to apoB-
containing lipoproteins with a higher afﬁnity in VLDL than LDL [21,
Fig. 4. Isolation of remnant lipoproteins (RLP) by immuno-afﬁnity gels and Western blot analysis. A. The isolated RLP sample or plasma was subjected to 12% SDS-polyacrylamide gel
electrophoresis and the proteins in the gel were transferred to a polyvinylidene diﬂuoride membrane by electroblot. The membranes were incubated with primary antibodies for 16 h.
The membranes were then incubated with a second antibody conjugated with alkaline phosphatase for 2 h, then visualized using the nitro blue tetrazolium/5-bromo-4-chloro-3-
indolylphosphate p-toluidine salt system. Anti-apoA-I antibodies and anti-apoB-100 antibodies were used for the immunostaining. As shown in (A), apoB100 and apoB48 were mainly
detected in RLP and a small amount of apoA1 was also detected in RLP in the presence and absence of heparin. B and C. Gel ﬁltration chromatography of the post-heparin plasma
(B) and RLP (C) in the presence and absence of THL was performed to separate the lipoproteins and monitored by apoB100 ELISA. ApoB100 was detected largely in LDL elution range
in post-heparin plasma in the presence and absence of THL. However, apoB100 in RLPwas found as themajor peak in theVLDL elution range in the presence of THL as previously reported.
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remnant lipoproteins in general. However, as the binding of LPL to TG-
rich lipoproteins in plasma is very weak and labile in vitro, it was difﬁ-
cult to detect LPL bound to RLP directly by an electrophoretic method
evenwith THL. LPLwas easily dissociated from RLP under electrophore-
sis. Therefore, gel ﬁltration chromatographywas used to isolate the RLP
and determine the presence of LPL bound to RLP by a highly sensitive
ELISA method.
Themain aim of the present studywas to reproduce as accurately as
possible the RLP proﬁle after lipase displacement from the arterial wall
by preventing ex vivo TG-rich lipoprotein hydrolysis by LPL. Previous re-
ports [12–14] have suggested that LPL in the post-heparin plasma is
mostly associated with cholesterol-rich lipoproteins such as LDL and
HDL. To investigate the hypothesis that these observationmaybe affect-
ed by ex vivo lipolysis, the LPL distribution across the entire lipoprotein
size range was evaluated in the post-heparin plasma. LPL dimers were
found associated with cholesterol-rich lipoproteins such as are typically
found in the HDL elution range. The results shown in Fig. 5 in theabsence of THL match the observations ﬁrst reported by Goldberg
et al. [12] and then by Vilella et al. [14], which indicate that, in the
post-heparin plasma, LPL is predominantly associated with LDL and
HDL. It has long been known that lipolysis is initiated intravascularly
and continues ex vivo [36], particularly in the post-heparin plasma,
when the amount of active LPL is increased several hundred fold.
These results were also conﬁrmed by Zambon et al. [20,21], emphasiz-
ing theneed for a complete inhibition of lipolytic activity in studies deal-
ing with post-heparin lipoprotein metabolism in order to minimize the
risk of ex vivo artifacts. In the present study, the active-site inhibitor of
LPL and THLwas used. THL almost completely inhibited lipolytic activity
in the post-heparin plasma.Moreover, THL did not affect the lipoprotein
elution proﬁle by gel ﬁltration when added to the post-heparin plasma
[21]. Hadvary et al. [22] and Looken et al. [23] suggested that LPL inhibi-
tion is due to the covalent binding of THL to Ser 132, which is 1 of the
residues of the catalytic triad of this enzyme. Looken et al. [23] also re-
ported that the binding of THL to LPL makes more stable and causes
the enzyme to form tetramers. However, we did not ﬁnd the signiﬁcant
Fig. 5. Effect of an LPL inhibitor (tetrahydrolipstatin: THL) on the gel ﬁltration proﬁles of LPL in the post-heparin plasma and RLP. A. A large amount of the LPL dimerswas found in theVLDL
elution range, with minor peaks in the LDL and HDL elution range in the presence of THL. However, in the absence of THL, a small amount of the LPL dimers was found in the VLDL elution
range, with major peaks in the HDL elution rang. B. The RLP, in the presence of THL, a large amount of the LPL dimer was found in the VLDL elution range withminor LDL and HDL elution
range peaks, a patternwhichwas very similarwith the elution proﬁle in the post-heparin plasma in the absence of THL, however no LPL dimerswere found in the VLDL elution range,with
a certain amount in theHDLelution range. A small amount of the LPL dimers in the plasma (C) and RLP (D) in thepresence and absence of THLwere found in theVLDL, LDL andHDLelution
range with a broad pattern of diffusion. These elution proﬁles are similar to the ones of the RLP isolated from the post-heparin plasma in the absence of THL.
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pre- and post-heparin plasma. Further studies by Heeren et al. [38] and
Zeng et al. [39] used THL for the analysis of postprandial TG-rich lipo-
proteins and LPL.
As shown in Fig. 5, the elution proﬁle of the RLP-LPL complex was
signiﬁcantly different between the post-heparin and pre-heparin plas-
ma aswell as RLP in the presence of THL. However, RLP-LPL elution pro-
ﬁle looked similar in all the cases in the absence of THL. Those cases
seemed to show the ﬁnal metabolized RLP proﬁles predominantly
existed in the LDL and HDL elution range. THL inhibited ex vivo LPL ac-
tivity in the post-heparin plasma maintained an elution proﬁle of RLP-
LPL complex in the VLDL elution range. These results show that active
LPL dimers are easily dissociated from VLDL and shifted to the HDL elu-
tion range, having ex vivo lipolytic activity continuously. LPL dimers
having the inactive form of LPL remained in the RLP. Therefore, the
LPL dimers in the RLP have no further activity for lipolysis, as shown
with the isolated RLP in the in vitro LPL activity assay (Table 4). As no
signiﬁcant effect of THL on the elution proﬁle in the pre-heparin plasma
or RLP was observed, it was suspected that the pre-heparin plasma or
RLP do not contain active LPL dimers. However, approximately 20% of
LPL dimers in pre-heparin plasma seemed to be active form. Because
after 2 h incubation of pre-heparin plasma at 37 °C, LPL dimers in RLP in-
creased consistently togetherwith the increase of FFA (data not shown).
As Brunzell et al. described [21,37], there are still a small amount of ac-
tive LPL dimers in pre-heparin plasma.
RLP-LPL complex elution proﬁle in the post-heparin plasma in the
presence of THL was similar to the elution proﬁles for TC and TG [27,
28]. However, the elution proﬁle of RLP-LPL in the pre-heparin plasmawas evidently different, as shown Fig. 5 (C, D). A greater amount of
LPL dimers in RLP detected in the HDL range than in the VLDL range, in-
dicating that smaller RLP particles carried a larger amount of the LPL di-
mers than larger RLP particles, which is the opposite proﬁle for TC and
TG. Unlike LPL, we have not found the presence of hepatic triglyceride
lipase (HTGL) in the form of RLP-HTGL complex in the VLDL elution
range in the post-heparin plasma. HTGL was found mostly at apoE-
richHDL range in the presence and absence of THL (manuscript in prep-
aration). Together with our previous report [32,40], it appears that
HTGL may not play as important a role in remnant metabolism as LPL,
although it has been generally believed that HTGL hydrolyzes small
remnants to LDL.
After the reduction in the TG content by LPL, the CM and VLDL par-
ticles have been generally believed to become smaller VLDL particles
such as intermediate density lipoproteins (IDL) as remnants. However,
several studies, including our own [32,39,41], reported that large VLDL
particles were the major structural components of remnant lipopro-
teins. If RLP were homogeneously metabolized TG-rich lipoproteins,
the particle size would be smaller than VLDL. However, RLP was pre-
dominantly of large VLDL size, which remained without further hydro-
lysis by the dimeric but inactive LPL. As RLP bears apoC1 and C3 [29], LPL
activity may be inhibited by the presence of these apolipoproteins on
the particles as shown in Table 4. ApoC1 and C3 may be transferred
from HDL particles with apoE at the time or after remnant generation
on the endothelium. Although the inhibition of LPL by apoC1 and C3
has been reported [42–50], it is not yet clear whether LPL dimers in
RLP are rendered inactive by those inhibitors in vivo. Once the inhibitors
on RLP disturb the lipolytic activity of LPL, large and ﬁxed sized VLDL
Fig. 6.ApoC1, apoC3 and apoE distribution across the lipoprotein elution range in the post-heparin plasma and RLP, with andwithout tetrahydrolipstatin (THL). A. ApoC1 elution range in
post-heparin plasma, B. ApoC1 elution range in post-heparin RLP, C. ApoC3 elution range in post-heparin plasma, D. ApoC3 elution range in pre-heparin RLP, E. ApoE elution range in post-
heparin plasma, F. ApoE elution range in post-heparin RLP.
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leased into the circulation as remnant lipoproteins along with the inac-
tive LPL dimers and its inhibitors. Inhibition of the lipolytic activity of
LPL by THL seems to be a similar phenomenon as that of the inhibition
of LPL by apoC1 or apoC3 in RLP, speciﬁcally high inhibition of LPL activ-
ity by apoC1.
Table 1 showed that the cases with TG N 150mg/dl carry signiﬁcant-
ly less amount of LPL than in cases with TG b 150 mg/dl. Namely, a
smaller amount of LPL dimers are carried by larger RLP particles com-
pared to a smaller RLP particles which carry a larger amount of LPL di-
mers per se. We reported previously that the LPL dimers in plasmawere inversely correlated with the RLP concentration and particle size
in patients with diabetes and MetS [32,33]. As the RLP-TG/RLP-C ratio
reﬂects the RLP particle size [51], we also reported the ﬁnding of a sig-
niﬁcant increase of the RLP-TG/RLP-C ratio after a fat load [52,53]. This
may be associated with the fact that LPL activity in the postprandial
plasma did not increase subsequent to the increase of RLP-C and RLP-
TG [24]. This means that the RLP particle size signiﬁcantly increased
after the fat load because of the insufﬁciency of LPL enzyme activity,
i.e. an inadequate capacity to hydrolyze the increased lipoprotein parti-
cles such as CM and VLDL on the endothelium in the postprandial
plasma.
Fig. 7. After the hydrolysis of CM and VLDL, most of the LPL is dissociated from endothelium into circulation as the LPL- RLP complex with dimeric but inactive form, possibly by the
presence of apoC1 and C3. A small amount (approximately 20%) of LPL bound to non-RLP fraction (possibly an active form) were also found in pre-heparin plasma.
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heparin plasma likely has important implications for the physiological
role of this enzyme as a multifunctional protein. Because of its ability
to simultaneously bind to the receptors and heparin-like substances,
LPL is able to efﬁciently mediate binding of lipoproteins to the cell sur-
face and to both of the endocytotic receptors, LRP-1 [16,17] and the
VLDL receptor [18]. Nykjaer et al. [19] found that the mediation of the
binding of lipoproteins to LRP-1 resided only with the LPL dimer. More-
over, other reports have demonstrated that inactive LPL dimers en-
hances the binding of TG-rich lipoproteins and β-VLDL to cell-surface
proteoglycans as well as LRP-1 [19,54,55]. It is therefore possible that
the LPL dimers associated with RLP particles play a physiological role
in vivo in the receptor-mediated remnant catabolism by affecting the
binding of RLP to LRP-1 and theVLDL receptor. RLP is known to be incor-
porated intomacrophages and theVLDL receptorwithout the additional
oxidation like as has been reported for LDL [56,57].
On the contrary as shown in Table 2, signiﬁcantly increased LPL
levels in RLP compared to the pre-heparin levels were found in
15 min after heparin administration associated with the decrease of
RLP-TG and the RLP-TG/RLP-C ratio. This means that active LPL dimers
detached from endothelium after heparin administration bound to cir-
culating RLP directly and hydrolyze RLP in blood, not on endothelium.
Because under such circumstances, RLP-C levels did not change, indicat-
ing that LPL dimers were not additionally detached from the endotheli-
um with newly generated RLP. This RLP-LPL complex found in
circulating blood may be the ﬁrst enzyme-substrate complex isolated
from the post-heparin plasma.
We have further investigated the biochemical characteristics of LPL
dimers in plasma and RLP in the post-heparin plasma. The plasma LPLTable 4
Inhibition of LPL activity by apoC1 and C3 in post-heparin
plasma.
LPL activity (%)
Control 100
Apo C1 10.3 ± 4.3
Apo C3 68.4 ± 9.8
RLP Undetecteddimerswere increased signiﬁcantly 15min after heparin administration
and returned to nearly the basal level (the pre-heparin level) after
60 min in Japanese subjects. The LPL concentration and activity in plas-
ma increased and decreased in parallel, but LPL activity in the presence
of THL was inhibited completely without concentration change in the
LPL dimers. The half-life of LPL in RLP was much longer than that of
total LPL in plasma. Interestingly, the immunoreactivity (or concentra-
tion) of the LPL dimers detected in the post-heparin plasma was signif-
icantly decreased after the addition of 2 h pre-incubation at 37 °C in the
absence of THL, while in the presence of THL the immunoreactivity of
the LPL dimers did not change under the same conditions. However,
the immunoreactivity of the LPL dimers in RLP did not change both in
the presence and absence of THL after the addition of 2 h pre-
incubation at 37 °C. These results suggest that LPL dimers in the active
form in the post-heparin plasma are easily degraded ex vivo, while the
LPL dimers in RLP in the inactive form are resistant to ex vivo degrada-
tion. Therefore, it has become clear that 2 different types of LPL dimers
exist in post-heparin plasma; one is active form mostly in HDL elution
range, the other is inactive form in RLP. Inactive LPL dimers in RLP
with apoC1 and C3 in vivo may become stable as in the presence of
THL andplay the role of interactingwith the LRP-1 and/or VLDL receptor
effectively. Active LPL dimers bound to non-RLPmaynot exist in plasma,
because the active LPL seems to be unstable at 37 °C in vivo. These re-
sults suggest the possibility that the measurement of the LPL activity
or concentration in the post-heparin plasma does not appropriately re-
ﬂect the physiological conditions, because there are 2 types of LPL di-
mers and the active form of LPL dimers is easily degraded in vivo and
in vitro.
In conclusion, the present study shows that most of the LPL in the
pre-heparin plasma was in the dimeric form and bound to RLP particles
as the inactive form.We isolated the newly generated RLP-LPL complex
from the plasma after heparin administration by inhibiting the ex vivo
lipolysis of LPL in the presence of THL. Furthermore, the RLP-LPL com-
plex isolated from the pre-heparin and post-heparin plasma was
found inactive, bearing apoC1 and apoC3. Inactive LPL dimers in RLP
may be important ligand to interact with receptors such as LRP-1 or
VLDL efﬁciently in vivo.
Therefore, we propose that the TG-rich lipoproteins bound to LPL di-
mers with inactive form is the new deﬁnition of remnant lipoproteins.
124 K. Sato et al. / Clinica Chimica Acta 461 (2016) 114–125Also the pre-heparin plasma LPL measurement may be more clinically
appropriate for the diagnosis of TG-rich lipoprotein metabolism than
LPL in the post-heparin plasma.
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